KR101751799B1 - A composition comprising extract of Parthenocissus tricuspidata or compound isolated therefrom for preventing or treating vascular disease - Google Patents

Abstract

The present invention relates to a method for producing ivy vines ( Parthenocissus tricuspidata extract or a compound isolated therefrom. The present invention also relates to a composition for preventing or treating vascular diseases. The ivy extract or the compound isolated therefrom is excellent in thrombin inhibitory activity and can be usefully used as a composition for preventing or treating vascular diseases.

Description

TECHNICAL FIELD [0001] The present invention relates to a composition for preventing or treating a vascular disease, which comprises ivy extract or a compound isolated therefrom,

The present invention relates to a method for producing ivy vines ( Parthenocissus tricuspidata extract or a compound isolated therefrom. The present invention also relates to a composition for preventing or treating vascular diseases.

In modern society, vascular disease is becoming a serious social problem. According to the statistics released by the National Statistical Office in 2010, vascular diseases including hypertensive diseases, ischemic heart diseases and cerebrovascular diseases are the second leading cause of death in Korea, followed by malignant tumors, , And the mortality rate of vascular disease was significantly increased in women over 65 years of age. Examples of the vascular diseases include thrombosis, arteriosclerosis, hypertension, angina pectoris, myocardial infarction, ischemic heart disease, heart failure, vascular restenosis, cerebral infarction, and stroke.

Thrombosis refers to a mass of blood clotted in blood vessels, consisting mainly of aggregates of platelets and fibrin, and is usually formed to prevent excessive bleeding of blood vessels. Under normal circumstances, soluble fibrinogen is converted to insoluble fibrin by thrombin, and a series of coagulation reactions are carried out to form a thrombus with the platelets. On the other hand, when the balance of external vascular injury, internal blood clotting factors, and thrombolytic factors is broken, blood clots may be over-formed.

In order to treat such improper thrombosis, various types of thrombotic agents have been developed and several types of thrombotic agents have been used clinically. The most commonly used thrombolytic agents are aspirin, heparin derivatives such as unfractionated heparin (UFH) or low molecular weight heparin (LMWH), and fondaparinux. Aspirin may reduce the risk of cardiovascular and cerebrovascular disease due to excessive thrombogenesis, but it has drawbacks such as the occurrence of upper gastrointestinal bleeding. In addition, unfractionated heparin and low-molecular-weight heparin do not require confirmation such as blood coagulation test and are simple but, in some cases, side effects such as heparin-induced thrombocytopenia (HIT) Care should be taken because there is a possibility of bleeding or bleeding. Fondaparinux, on the other hand, has the disadvantage that it is comparable to or superior to the effects of unfractionated heparin and low molecular weight heparin, but is expensive (Mackman, NT, 2008; Gross, PL et al., 2008; Lee, KA et al., 2005).

Since the drugs made of the above-mentioned chemicals cause various problems to the human body, a compound derived from natural materials showing the same effect while reducing the side effects of the drug has recently become popular as a thrombotic treatment agent. Flavonoids, alkaloids, stilbenoids, phenolic compounds, etc. have been reported to be used as antithrombotic agents derived from natural products (Xiang, et al., 2008).

Ivy is a deciduous broad-leaved vine plant of the dicotyledonous gabbrook grape. It is also called "常 常 常 常." And is distributed in Korea, Japan, Taiwan, and China. The stem of the ivy grows up to 10m or more in length, and the tendon is opposite to the leaf and has a rounded adsorption muscle at the end, which does not fall well on the wall or rock wall. Leaves are alternate phyllotaxis, 10-20cm wide egg-shaped. Leaf tip is pointed and split into 3 pieces. There are no hairs on the front side. There are hairs on the back vein and irregular sawtooth on the edge. In one room, the roots and the stem are used as the medicine of the present (錦 錦), releasing the ejaculation, and relieving the pain of joints and muscles. In addition, the ivy has been reported to contain abundant phenolic compounds (Kim, HJ et al., 1995; Paulino, LA et al., 1991; Toshiyuki, T. et al., 1998; , M. et al., 2004).

In the course of conducting various studies on ivy (Korean Patent No. 991279; Korean Patent Publication No. 2010-0115404; Korean Patent Laid-open Publication No. 2013-0082249), the present inventors have found that the ivy extract and the compound The present invention can be completed by confirming that the vascular disease is prevented or treated.

Korean Patent No. 991279 (composition for the prevention and treatment of inflammatory diseases containing a novel compound isolated from ivy extract as an active ingredient, registered on October 26, 2010) Korean Patent Publication No. 2010-0115404 (Insecticidal composition of solvent extract of ivy, published on October 28, 2010) Korean Patent Laid-Open Publication No. 2013-0082249 (Composition for preventing or improving metabolic diseases containing ivy extract, published on Jul. 19, 2013)

Alban, S., Natural and synthetic glycosaminoglycans-Molecular characteristics as the basis of distinct drug profiles, Hamostaseologie, 28 (1-2), 51-61, 2008. Gross, P. L. et al., New anticoagulants for treatment of venous thromboembolism, Arterioscler. Thromb. Vasc. Biol., 28 (3), 380-386, 2008. Kim, H. J. et al., Two new antioxidant stilbene dimers, parthenostilbenins A and B from Parthenocissus tricuspidata, Planta. Med., 71 (10), 973-976, 1995. Lee, K. A. et al., Antiplatelet and antithrombotic activities of methanol extracts of Usnea longissima, Phytother. Res., 19 (12), 1061-1064, 2005. Lee, S. U. et al., Caffeoylglycolic and caffeoylamino acid derivatives, halfmers of L-chicoric acid, as new HIV-1 integrase inhibitors, Eur. J. Med. Chem., 42 (10), 1309-1315, 2007. Mackman, N. T., Triggers, targets and treatments for thrombosis, Nature, 451, 914, 2008. Paulino, L. A. et al., A. resveratrol dimer from Parthenocissus tricuspidata, Phytochemistry, 30, 3144-3146, 1991. Saleem, M. et al., Antioxidant caffeic acid derivatives from leaves of Parthenocissus tricuspidata, Arch. Pharm. Res., 27 (3), 300-304, 2004. Toshiyuki, T. et al., A. resveratrol dimer from Parthenocissus tricuspidata, Phytochemistry, 48 (7), 1241-1243, 1998. Xiang, et al., Strategies for antiplatelet targets and agents., Thromb. Res., 123, 35-49, 2008.

It is an object of the present invention to provide a composition for preventing or treating vascular diseases comprising ivy extract or a compound isolated therefrom. More specifically, the compound of formula (I) is selected from the group consisting of ivyvine extract or methyl 3,4-dihydroxycinnamate (compound 1) and caffeoylglycolic acid methyl ester (compound 2) The present invention provides a composition for preventing or treating vascular diseases, which comprises at least one compound.

The present invention relates to a process for the preparation of a compound of formula (I) wherein at least one compound of methyl 3,4-dihydroxycinnamate (compound 1) and caffeoylglycolic acid methyl ester (compound 2) Containing ivy vines ( Parthenocissus The present invention relates to a composition for preventing or treating a vascular disease containing an extract of tricuspidata .

[Chemical Formula 1]

The ivy extract may be extracted with water, C1-C4 lower alcohol or a mixed solvent thereof.

The vascular disease may be a disease selected from thrombosis, arteriosclerosis, hypertension, angina pectoris, myocardial infarction, ischemic heart disease, heart failure, vascular restenosis, cerebral infarction and stroke.

The present invention relates to methyl 3,4-dihydroxycinnamate (compound 1) and caffeoylglycolic acid methyl ester (compound 1) which are separated from the ivy vine ( Parthenocissus tricuspidata ) Compound (2)) for preventing or treating vascular diseases.

In another aspect, the present invention provides a process for preparing a compound of formula (I), which comprises reacting methyl 3,4-dihydroxycinnamate (compound 1) and caffeoylglycolic acid methyl ester (compound 2) ( Parthenocissus tricuspidata ) extract containing at least one compound of the formula (I).

Hereinafter, the present invention will be described in detail.

The present invention relates to a composition for preventing or treating vascular diseases comprising ivy extract or a compound isolated therefrom, wherein the vascular disease is selected from the group consisting of thrombosis, arteriosclerosis, hypertension, angina pectoris, myocardial infarction, ischemic heart disease, Restenosis, cerebral infarction and stroke. Further, the thrombosis may include thrombotic phlebitis, arterial embolism, coronary artery thrombosis, cerebral artery thrombosis, peripheral vascular thrombosis, deep vein thrombosis, arterial thrombosis, venous thrombosis, chronic arterial occlusion, menopause, cerebral embolism and the like.

The ivy extract of the present invention can be obtained by extracting ivy with water, C1 to C4 lower alcohols or a mixed solvent thereof. Examples of the C1 to C4 lower alcohols include methanol, ethanol, propanol, isopropanol, and butanol. The ivy extract may be a fraction obtained by fractionation with an organic solvent, and dichloromethane, ethyl acetate and n-butanol may be used as the organic solvent.

Also, the compound isolated from the ivy vine of the present invention may be prepared by extracting the ivy vine with water, C1 to C4 lower alcohol or a mixed solvent thereof to prepare ivy extract; Sequentially fractionating said ivy extract with dichloromethane, ethyl acetate and n-butanol; And separating the compounds by chromatography on each of the fractions.

The chromatography can be carried out by silica gel column chromatography, RP-18 column chromatography, thin layer chromatography (TLC), ion exchange resin chromatography ), Medium pressure liquid chromatography, silica gel vacuum liquid chromatography and high performance liquid chromatography (HPLC).

Meanwhile, the compound of the present invention can be synthesized according to a conventional method in the art, and can also be prepared as a pharmaceutically acceptable salt.

The present invention also relates to a method for the production of Parthenocissus tricuspidata extract or methyl 3,4-dihydroxycinnamate (Compound 1) and caffeoylglycolic acid methyl ester , Compound (2)). The present invention also provides a pharmaceutical composition for preventing or treating vascular diseases. The pharmaceutical composition containing the extract or the compound may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols or the like, oral preparations, suppositories and sterilized injection solutions, Can be used. Examples of carriers, excipients and diluents that can be contained in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , Methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient, such as starch, calcium carbonate, sucrose, Or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

The dosage of the pharmaceutical composition comprising the extract or compound of the present invention will vary depending on the age, sex, body weight, the specific disease or condition to be treated, the severity of the disease or condition, the route of administration, and the judgment of the prescriber. Dosage determinations based on these factors are within the level of ordinary skill in the art and generally the dosage ranges from 0.01 mg / kg / day to approximately 2000 mg / kg / day. A more preferable dosage is 1 mg / kg / day to 500 mg / kg / day. The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way.

The pharmaceutical composition comprising the extract or compound of the present invention can be administered to mammals such as rats, livestock, humans, and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection. In addition, the extract or the compound of the present invention has little toxicity and side effects, so it can be safely used for long-term administration for preventive purposes.

The present invention provides a health functional food for preventing or ameliorating vascular diseases including ivy vine extract. In addition, the health functional food may be supplemented with a pharmaceutically acceptable food-aid additive, and there is no particular limitation on the kind of the health functional food. Examples of the food to which the above extract can be added include dairy products such as meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen noodle, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include health functional foods in a conventional sense. The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 ml of the composition of the present invention. In addition to the above, the health functional food of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, , Carbonating agents used in carbonated beverages, and the like. In addition, the health functional food of the present invention may include natural fruit juice, fruit juice drink, and pulp for producing vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health functional food of the present invention.

The present invention relates to a composition for preventing or treating vascular diseases comprising Parthenocissus tricuspidata extract or a compound isolated therefrom. The ivy extract or the compound isolated therefrom is excellent in thrombin inhibitory activity and can be usefully used as a composition for preventing or treating vascular diseases.

Figure 1 shows the relative thrombin time (%) of the control (dimethyl sulfoxide, DMSO), aspirin 75 μg / ml and 100 μg / ml, ivy water extract, methanol extract, ethyl acetate fraction, It is a picture.

Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein but may be embodied in other forms. Rather, the intention is to provide an exhaustive, complete, and complete disclosure of the principles of the invention to those skilled in the art.

≪ Example 1: Preparation of ivy extract and separation of compound >

The stalks of Parthenocissus tricuspidata used in the present invention were collected at Palgongsan, Daegu, 50 ℓ of water was added to 10 ㎏ of the ivy stem and extracted at 90 캜 for 5 hours. The extract was freeze-dried to obtain 985 g of powder. Further, 10 kg of the ivy stalk was refluxed with methanol (40 L × 3 times) to obtain 1.2 kg of methanol extract. The methanol extract was suspended in 2.1 L of water and dichloromethane (3 L × 3 times), ethyl acetate (0.8 L × 3 times) and n-butanol (0.8 L × 3 times) were added successively and dichloromethane, ethyl acetate And fractions containing the n-butanol fraction and finally the water layer residue were obtained. Then, the compounds of the present invention were isolated from the fraction of ethyl acetate having a relatively high blood coagulation inhibitory effect by the thrombin time assay for the ivy water extract, the methanol extract, the three fractions and the water layer residue.

The ethyl acetate fraction (108.6 g) was purified by column chromatography on silica gel column (15 × 60 cm, 63-200 μm particle size) and dichloromethane-methanol (gradient from 100: 1 to 0: 1 [v: (Fr. EA1-Fr. EA10). Among these, the thrombin time assay was used to identify the fraction of Fr. EA4, Fr. EA6, Fr. EA8 was obtained. Fr. The EA6 subfraction was obtained from RS Tech. Optima. Pak., C18 column (column size: 10 x 250 mm, particle size: 5 탆). First, 0-70 minutes is 0.1% [w / v] of formic acid containing 40% [v / v] methanol using water as the mobile phase compound _{1 (6.8mg, t R = 60.1min} ) and compound 2 ( 58.5 mg, t _R = 65.7 min). Then, methanol-water (gradient from 40% to 100% [v / v]) was applied for 70 to 75 minutes in a concentration gradient condition, and 100% methanol was used as a mobile phase for 75 to 80 minutes. Respectively.

< Example  2. Identification of the physicochemical structure of the compounds isolated from ivy>

Example 2-1. Methyl 3,4-dihydroxy cinnamate (Compound 1)

methyl 3,4-dihydroxycinnamate;

white powder;

_{^{1 H-NMR (Methanol- d 4}} , 400 MHz) δ 7.54 (1H, d, J = 16.0 Hz, H-7), 7.03 (1H, d, J = 2.0 Hz, H-2), 6.94 (1H, d, J = 2.0, 8.0 Hz , H-6), 6.78 (1H, d, J = 8.4 Hz, H-5), 6.26 (1H, d, J = 16.0 Hz, H-8), 3.76 (3H, s, -OCH _3);

_{^{13 C-NMR (Methanol- d 4}} , 100 MHz) δ 170.1 (-COO-), 149.9 (C-4), 148.3 (C-3), 128.9 (C-6), 122.4 (C-1), 116.9 (C-2), 115.6 ( C-5), 52.1 (-OCH 3).

Example 2-2. Caffe oil glycolic acid methyl ester (Compound 2)

caffeoylglycolic acid methyl ester;

white amorphous powder;

_{^{1 H-NMR (Methanol- d 4}} , 400 MHz) δ 7.61 (1H, d, J = 16.0 Hz, H-7), 7.06 (1H, d, J = 2.0 Hz, H-2), 6.95 (1H, d, J = 2.0, 8.0 Hz, H-6), 6.78 (1H, d, J = 8.0 Hz, H-5), 6.32 (1H, d, J = 16.0Hz, H- s, H-10), 3.75 (-OCH 3);

_{^{13 C-NMR (Methanol- d 4}} , 100 MHz) δ 170.6 (11-COO-), 168.5 (9-COO-), 150.0 (C-4), 148.2 (C-7), 147.0 (C-3) , 127.7 (C-1), 123.3 (C-6), 116.7 (C-5), 115.4 (C-2), 114.1 (C-8), 61.7 (C-10), 52.8 (-OCH 3).

Example 3 Thrombin Time Assay < RTI ID = 0.0 >

In order to measure thrombin time, the extracts of Ivy, Ix, ethyl acetate and compounds I and II of Example 1 were dissolved in DMSO (dimethyl sulfoxide), respectively, and the final concentration of the assay was 100 μg / ml Was treated with 50 占 퐇 of human thrombin (Sigma Co., USA) at 37 占 폚 for 10 minutes. Then, 50 μl of 20 mM calcium chloride was mixed with 100 μl of standard human plasma (Siemens, Marburg, Germany), and the time until the plasma coagulated was measured using an automatic blood coagulation analyzer (Sysmex CA-540, Japan) (Lee, SU et al., 2007). At this time, 75 μg / ml and 100 μg / ml of aspirin (Sigma Co., USA) were used as the positive control group and DMSO was used as the negative control group.

The relative thrombin time (%) of the extract and compound is shown in Table 1 below.

Condition Relative thrombin time (%) The negative control (DMSO) 100 The positive control (aspirin, 75 占 퐂 / ml) 138 A positive control (aspirin, 100 mu g / ml) 181 The ivy water extract (100 mu g / ml) of Example 1 113 (100 mu g / ml) of the ivy vine methanol extract of Example 1, 118 The ivy vine ethyl acetate fraction of Example 1 (100 [mu] g / ml) 125 Compound 1 (100 占 퐂 / ml) 174 Compound 2 (100 占 퐂 / ml) 148

As shown in Table 1, 113% of ivy water extract, 118% of ivy vinegar extract, 125% of ivy vine ethyl acetate fraction, 174% of compounds 1 and 2, and 148% of relative thrombin time %). At this time, the compounds 1 and 2 exhibited relative thrombin time (%) similar to 75 μg / ml and 100 μg / ml of aspirin, and it was confirmed that the blood coagulation inhibition effect was excellent by inhibiting thrombin activity and delaying the blood coagulation time.

<Example 4: Toxicity test>

Example 4-1. Acute toxicity

This experiment was conducted to investigate the toxicity to the animal body in an acute (within 24 hours) when an excessive amount of methanol extract of the ivy extract of Example 1 of the present invention was consumed in a short period and determine the mortality rate. Twenty ICR mice were prepared, and 10 mice were assigned to each group. In the control group, only 30% PEG-400 was administered, and the experimental group was orally administered with the methanol extract of ivy vine of Example 1 at a concentration of 1.0 g / kg. After 24 hours of administration, the respective mortality rates were examined. As a result, both the control group and the test group administered with the methanol extract of ivy were alive.

Example 4-2. Organ organs toxicity test in experimental group and control group

The long-term toxicity test was conducted to examine the effects of C57BL / 6J mice on each organ (tissues) of the animal. To the test group administered with 1.0 g / kg of the methanol extract of the ivy extract of Example 1 and the solvent alone Blood samples were taken 8 weeks after the control animals and the concentrations of glutamate-pyruvate transferase (GPT) and blood urea nitrogen (BUN) in the blood were measured using Select E (vital scientific NV, Netherland). As a result, GPT, which is known to be related to hepatotoxicity, and BUN, which is known to be related to renal toxicity, showed no significant difference compared to the control group. In addition, liver and kidney were cut from each animal and histological observation was performed with an optical microscope through a conventional tissue section production process, but no abnormal abnormalities were observed.

&Lt; Formulation Example 1 >

Formulation Example 1-1. Manufacture of tablets

200 g of methanol extract of ivy vine of Example 1 of the present invention was mixed with 175.9 g of lactose, 180 g of potato starch and 32 g of colloidal silicic acid. To this mixture was added a 10% gelatin solution, which was pulverized and passed through a 14-mesh sieve. This was dried, and a mixture obtained by adding 160 g of potato starch, 50 g of talc and 5 g of magnesium stearate was made into tablets.

Formulation Example 1-2. Injection preparation

1 g of the methanol extract of ivy vine of Example 1, 0.6 g of sodium chloride and 0.1 g of ascorbic acid were dissolved in distilled water to make 100 ml. This solution was placed in a bottle and sterilized by heating at 20 DEG C for 30 minutes.

<Formulation Example 2: Food Preparation>

Formulation Example 2-1. Manufacture of cooking seasonings

The oyster mushroom methanol extract of Example 1 of the present invention was adjusted to 0.2 to 10.0% by weight to prepare a cooking sauce for health promotion.

Formulation Example 2-2. Manufacture of flour food products

A food for health promotion was prepared by adding to the flour 0.1 to 5.0% by weight of methanol extract of ivy vine of Example 1 and preparing bread, cake, cookie, cracker and noodle by using this mixture.

Preparation Example 2-3. Manufacture of soups and gravies

The meat extract for health promotion, the soup of the noodles and the juice were prepared by adding 0.1 to 1.0% by weight of the methanol extract of Ivy Vine of Example 1 to the soup and the juice.

Formulation Example 2-4. Manufacture of dairy products

The methanol extract of ivy vine of Example 1 was added to milk in an amount of 0.1 to 1.0 wt%, and various dairy products such as butter and ice cream were prepared using the milk.

Formulation Example 2-5. Manufacture of vegetable juice

Healthy vegetable juice was prepared by adding 0.5 g of methanol extract of ivy vine of Example 1 to 1,000 ml of tomato or carrot juice.

Formulation Example 2-6. Manufacture of fruit juices

Healthy fruit juice was prepared by adding 0.1 g of methanol extract of ivy vine of Example 1 to 1,000 ml of apple or grape juice.

Claims (8)

At least one compound selected from the group consisting of methyl 3,4-dihydroxycinnamate (compound 1) and caffeoylglycolic acid methyl ester (compound 2) represented by the following formula 1 as an active ingredient ( Parthenocissus tricuspidata ) extract, which comprises an effective amount of a composition for preventing or treating thrombosis.
[Chemical Formula 1]

The method according to claim 1,
Wherein said ivy extract is obtained by extracting ivy with water, C1-C4 lower alcohol or a mixed solvent thereof. The method according to claim 1,
Wherein the thrombosis is selected from the group consisting of thrombotic phlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, peripheral vascular thrombosis, deep vein thrombosis, arterial thrombosis, venous thrombosis, chronic arterial occlusion, menopausal color and cerebral embolism. &Lt; / RTI &gt; Methyl 3,4-dihydroxycinnamate (Compound 1) and caffeoylglycolic acid methyl ester (Compound 2) of the following Chemical Formula 1 isolated from the ivy vine ( Parthenocissus tricuspidata ) Or a pharmaceutically acceptable salt thereof, as an active ingredient.
[Chemical Formula 1]

5. The method of claim 4,
Wherein the thrombosis is selected from the group consisting of thrombotic phlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, peripheral vascular thrombosis, deep vein thrombosis, arterial thrombosis, venous thrombosis, chronic arterial occlusion, menopausal color and cerebral embolism. &Lt; / RTI &gt; At least one compound selected from the group consisting of methyl 3,4-dihydroxycinnamate (compound 1) and caffeoylglycolic acid methyl ester (compound 2) represented by the following formula 1 as an active ingredient ( Parthenocissus tricuspidata ) extract of the present invention for preventing or improving thrombosis.
[Chemical Formula 1]

The method according to claim 6,
Wherein said ivy extract is obtained by extracting ivy with water, C1-C4 lower alcohol or a mixed solvent thereof. The method according to claim 6,
Wherein the thrombosis is selected from the group consisting of thrombotic phlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, peripheral vascular thrombosis, deep vein thrombosis, arterial thrombosis, venous thrombosis, chronic arterial occlusion, menopausal color and cerebral embolism. For the prevention or amelioration of the health functional food.

Images